The pharmacologic management of cancer pain

Journal of Palliative Medicine

Volumn 10, Issue 6, 2007, Pages 1369-1394

  Cleary, James F ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CARBAMAZEPINE; CODEINE; DESIPRAMINE; DULOXETINE; EMLA; FENTANYL; FLUOXETINE; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; KETOROLAC; LAMOTRIGINE; LIDOCAINE; METHADONE; MEXILETINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; OXYCODONE; OXYMORPHONE; PARACETAMOL; PAROXETINE; PHENYTOIN; SODIUM CHANNEL BLOCKING AGENT; TRAMADOL; UNINDEXED DRUG; VENLAFAXINE;

ANALGESIC ACTIVITY; ANTINOCICEPTION; ATAXIA; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CONFUSION; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG GLUCURONIDATION; DRUG RECEPTOR BINDING; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY INJURY; LEG EDEMA; LIVER TOXICITY; MYOCLONUS; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NYSTAGMUS; PLASMA CLEARANCE; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; TRIGEMINUS NEURALGIA; WORLD HEALTH ORGANIZATION;

ANALGESICS, OPIOID; HUMANS; NEOPLASMS; PAIN; PALLIATIVE CARE; UNITED STATES;

EID: 37349111484     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2007.9842     Document Type: Review

References (267)

1. Portenoy RK, Ugarte C, Fuller I, Haas G: Population-based survey of pain in the United States: Differences among white, African American, and Hispanic subjects. J Pain 2004;5:317-328.
2. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, Smart-Curley T, Kemeny N, Norton L, Hoskins W, et al: Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994;3:183-189.
3. Vuorinen E: Pain as an early symptom in cancer. Clin J Pain 1993;9:272-278.
4. Mercadante S, Armata M, Salvaggio L: Pain characteristics of advanced lung cancer patients referred to a palliative care service. Pain 1994;59:141-145.
5. Hongo T, Watanabe C, Okada S, Inoue N, Yajima S, Fujii Y, Ohzeki T: Analysis of the circumstances at the end of life in children with cancer: Symptoms, suffering and acceptance. Pediatr Int 2003;45:60-64.
6. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ: Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596.
7. Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ: Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med 1997;127:813-816.
8. Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang LL: "We don't carry that" - Failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med 2000;342:1023-1026.
9. Hall S, Gallagher RM, Gracely E, Knowlton C, Wescules D: The terminal cancer patient: Effects of age, gender, and primary tumor site on opioid dose. Pain Med 2003;4:25-34.
10. Johnson VM, Teno JM, Bourbonniere M, Mor V: Palliative care needs of cancer patients in U.S. nursing homes. J Palliat Med 2005;8:273-279.
11. Lyne ME, Coyne PJ, Watson AC: Pain management issues for cancer survivors. Cancer Pract 2002;10(Suppl 1):S27-32.
12. Macdonald L, Bruce J, Scott NW, Smith WC, Chambers WA: Long-term follow-up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer 2005;92:225-230.
13. World Health Organization: Cancer Pain Relief. Geneva: World Health Organization, 1986.
14. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F: A validation study of the WHO method for cancer pain relief. Cancer 1987;59:850-856.
15. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA: Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain 1995;63:65-76.
16. Zernikow B, Meyerhoff U, Michel E, Wiesel T, Hasan C, Janssen G, Kuhn N, Kontny U, Fengler R, Gortitz I, Andler W: Pain in pediatric oncology - Children's and parents' perspectives. Eur J Pain 2005;9:395-406.
17. Jadad AR, Browman GP: The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA 1995;274:1870-1873.
18. Reidenberg MM: Pain control and the World Health Organization analgesic ladder letter; comment. JAMA 1996;275:11.
19. Twycross R, Lickiss N: Pain control and the World Health Organization analgesic ladder. JAMA 1996;275:11.
20. Ventafridda V, Stjernsward J: Pain control and the World Health Organization analgesic ladder. JAMA 1996;275:835-836.
21. Jacox A, Carr DB, Payne R: Management of Cancer Pain. Clinical Practice Guideline No. 9., U.S.D.o.H.a.H.S. Agency for Health Care Policy and Research, Public Health Service, 1994, AHCPR Publication No. 94-0592. Rockville, MD.
22. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-284.
23. Miaskowski, C, Cleary JF, Burney R: Guideline for the Management of Cancer Pain in Adults and Children. Glenview, IL: American Pain Society, 2005.
24. Ashby MA, Fleming BG, Brooksbank M, Rounsefell B, Runciman WB, Jackson K, Muirden N, Smith M: Description of a mechanistic approach to pain management in advanced cancer. Preliminary report. Pain 1992;51:153-161.
25. Benedetti C, Brock C, Cleeland C, Coyle N, Dube JE, Ferrell B, Hassenbusch S, Janjan NA, Lema MJ, Levy MH, Loscalzo MJ, Lynch M, Muir C, Oakes L, O'Neill A, Payne R, Syrjala KL, Urba S, Weinstein SM: NCCN Practice Guidelines for Cancer Pain. Oncology (Huntingt) 2000;14:135-150.
26. Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A, Porzio G, Marchetti P, Varrassi G: Use of strong opioids in advanced cancer pain: A randomized trial. J Pain Symptom Manage 2004;27:409-416.
27. Joranson D, Rajagopal M, Gilson A: Improving access to opioid analgesics for palliative care in India. J Pain Symptom Manage 2002;24:152.
28. Joranson DE: Improving availability of opioid pain medications: Testing the principle of balance in Latin America. J Palliat Med 2004;7:105-114.
29. Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F: Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 2005;19:477-484.
30. Cleary JF: A day in the life of European palliative care. Palliat Med 2005;19:442-443.
31. International Narcotic Control Board: Availability of opiates for medical needs: Report of International Narcotics Control Board for 1995. Vienna: International Narcotic Control Board, 1996.
32. Pasternak GW: Insights into mu opioid pharmacology the role of mu opioid receptor subtypes. Life Sci 2001;68:2213-2219.
33. Pasternak GW: The pharmacology of mu analgesics: from patients to genes. Neuroscientist 2001;7:220-221.
34. Inturrisi CE: Clinical pharmacology of opioids for pain. Clin J Pain 2002;18(4 Suppl):S3-13.
35. Yaksh TL: Central pharmacology of nociceptive transmission. In: Textbook of Pain, 5th ed. Philadelphia: Elsevier Churchill Livingston. 2006, pp. 371-414.
36. Lemberg KK, Kontinen VK, Siiskonen AO, Viljakka KM, Yli-Kauhaluoma JT, Korpi ER, Kalso EA: Antinociception by spinal and systemic oxycodone: Why does the route make a difference? In vitro and in vivo studies in rats. Anesthesiology 2006;105:801-812.
37. Wiffen PJ, Edwards JE, Barden J, McQuay MJ: Oral morphine for cancer pain. Cochrane Database Syst Rev 2003(4):CD003868.
38. Gourlay GK, Cherry DA, Onley MM, Tordoff SG, Conn DA, Hood GM, Plummer JL: Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain. Pain 1997;69:295-302.
39. Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J: Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formdxulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 2002;23:292-300.
40. Glare PA, Walsh TD: Clinical pharmacokinetics of morphine. Ther Drug Monit 1991;13:1-23.
41. Osborne R, Joel S, Trew D, Slevin M: Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther 1990;47:12-19.
42. Ribeiro, M.D., S.P. Joel, and G. Zeppetella, The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage 2004;27:434-439.
43. Watterson G, Howard R, Goldman A: Peripheral opioids in inflammatory pain. Arch Dis Child 2004;89:679-681.
44. Babul N, Darke AC: Disposition of morphine and its glucuronide metabolites after oral and rectal administration: Evidence of route specificity. Clin Pharmacol Ther 1993;54:286-292.
45. Lotsch J, Skarke C, Schmidt H, Liefhold J, Geisslinger G: Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clin Pharmacol Ther 2002;72:151-162.
46. Buetler TM, Wilder-Smith OH, Wilder-Smith CH, Aebi S, Cerny T, Brenneisen R: Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers. Br J Anaesth 2000;84:97-99.
47. Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML: Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther 2000;68:667-676.
48. Penson RT, Joel SP, Clark S, Gloyne A, Slevin MLP: Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001;90:1810-1866.
49. Morley JS, Miles JB, Wells JC, McKibbin PE, Seabra L: Paradoxical pain Meeting abstract. 7th World Congress on Pain, August 1993.
50. Klepstad P, Borchgrevink PC, Dale O, Zahlsen K, Aamo T, Fayers P, Fougner B, Kaasa S: Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. Palliat Med 2003;17:679-687.
51. Quigley C, Joel S, Patel N, Baksh A, Slevin M: Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain. Palliat Med 2003;17:185-190.
52. Sawe J, Kager L, Svensson Eng JO, Rane A: Oral morphine in cancer patients: In vivo kinetics and in vitro hepatic glucuronidation. Br J Clin Pharmacol 1985;19:495-501.
53. Crotty B, Watson KJ, Desmond PV, Mashford ML, Wood LJ, Colman J, Dudley: Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989;36:501-506.
54. Milne RW, Nation RL, Somogyi AA: The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996;28:345-472.
55. Hasselstrom J, Eriksson S, Persson A, Rane A, Svensson JO, Sawe J: The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990;29:289-297.
56. Osborne R, Joel S, Grebenik K, Trew D, Slevin M: The pharmacokinetics of morphine and morphine glucuronides in kidney failure [see comments]. Clin Pharmacol Ther 1993;54:158-167.
57. Dean M: Opioids in renal failure and dialysis patients. J Pain Symptom Manage 2004;28:497-504.
58. de Craen AJ, Di Giulio G, Lampe-Schoenmaeckers JE, Kessels AG, Kleijnen J: Analgesic efficacy and safety of paracetamol-codeine combinations versus paracetamol alone: A systematic review. BMJ 1996;313:321-325.
59. Moore A, Collins S, Carroll D, McQuay H, Edwards J: Single dose paracetamol (acetaminophen), with and without codeine, for postoperative pain. Cochrane Database Syst Rev, 2000(2):CD001547.
60. Guay D, Awni W, Halstenson C, Findlay J, Opsahl J, Abraham P, Jones E, Matzke J: Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol 1988;27:983-987.
61. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I, Brockmoller J: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007;7:257-265.
62. Yue QY, Alm C, Svensson JO, Sawe J: Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther Drug Monit 1997;19:539-542.
63. Mikus G, Trausch B, Rodewald C, Hofmann U, Richter K, Gramatte T, Eichelbaum M: Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 1997;61:459-466.
64. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH: Codeine and morphine in extensive and poor metabolizers of sparteine: Pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996;51:289-295.
65. Yue QY, Sawe J: Different effects of inhibitors on the Oand N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997;52:41-47.
66. Yue QY, Iselius L, Sawe J: Indices and graphical approaches for the detection of interindividual and interethnic variations in codeine metabolism. Br J Clin Pharmacol 1997;44:239-244.
67. Caraco Y, Sheller J, Wood AJ: Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999;290:413-422.
68. Williams DG, Patel A, Howard RF: Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br J Anaesth 2002;89:839-845.
69. Guay D, Awni W, Findlay J, Halstenson C, Abraham P, Opsahl J, Jones E, Matzke G: Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988;43:63-71.
70. Gibson TP: Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 1996;101:47S-53S.
71. Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH: The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-644.
72. Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K: Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypalgesia effect of tramadol. Clin Pharmacol Ther 2005;77:312-323.
73. Pedersen RS, Damkier P, Brosen K: Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006;62:513-521.
74. De Witte JL, Schoenmaekers B, Sessler DI, Deloof T: The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 2001;92:1319-1321.
75. Jones D, Story DA: Serotonin syndrome and the anaesthetist. Anaesth Intens Care 2005;33:181-187.
76. Grond S, Radbruch l, Meuser T, Loick G, Sabatowski R, Lehmann KA: High-dose tramadol in comparison to low-dose morphine for cancer pain relief. J Pain Symptom Manage 1999;18:174-179.
77. Moore RA, McQuay HJ: Single-patient data meta-analysis of 3453 postoperative patients: Oral tramadol versus placebo, codeine and combination analgesics. Pain 1997;69:287-294.
78. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS: Tramadol relieves pain and allodynia in polyneuropathy: A randomised, double-blind, controlled trial. Pain 1999;83:85-90.
79. Duhmke RM, Cornblath DD, Hollingshead JR: Tramadol for neuropathic pain. Cochrane Database Syst Rev 2004(2):CD003726.
80. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A: Anticonvulsant drugs for acute and chronic pain [In Process Citation]. Cochrane Database Syst Rev 2000(3):CD001133.
81. Jick H, Derby LE, Vasilakis C, Fife D: The risk of seizures associated with tramadol. Pharmacotherapy 1998;18:607-611.
82. Gardner JS, Blough D, Drinkard CR, Shatin D, Anderson G, Graham D, Alderfer R: Tramadol and seizures: A surveillance study in a managed care population. Pharmacotherapy 2000;20:1423-1431.
83. Gasse C, Derby L, Vasilakis-Scaramozza C, Jick H: Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000;20:629-634.
84. Findlay JW, Jones EC, Welch RM: Radioimmunoassay determination of the absolute oral bioavailabilities and Odemethylation of codeine and hydrocodone in the dog. Drug Metab Dispos 1979;7:310-314.
85. Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EM: CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993;54:463-472.
86. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004;57:287-297.
87. Luo X, Pietrobon R, Hey L: Patterns and trends in opioid use among individuals with back pain in the United States. Spine 2004;29:884-890; discussion 891.
88. Litkowski LJ, Christenson SE, Adamson DN, Van Dyke T, Han SH, Newman KB: Analgesic efficacy and tolerability of oxycodone 5 mg/ibuprofen 400 mg compared with those of oxycodone 5 mg/acetaminophen 325 mg and hydrocodone 7.5 mg/acetaminophen 500 mg in patients with moderate to severe postoperative pain: A randomized, double-blind, placebo-controlled, single-dose, parallel-group study in a dental pain model. Clin Ther 2005;27:418-429.
89. Marco CA, Plewa MC, Buderer N, Black C, Roberts A: Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: A double-blind, randomized, controlled trial. Acad Emerg Med 2005;12:282-288.
90. Bruera E, Sloan P, Scott J, Suarez-Almazor M: A randomized, double-dummy, crossover trial comparing slowrelease (SR) to immediate release (IR) hydromorphone (HM) for the treatment of cancer pain [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1995:14.
91. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr., Dornseif BE, Damask MC: Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage 2002;23:355-368.
92. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL: Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol 1981;21:152-156.
93. Hagen N, Thirlwell MP, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC: Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995;35:37-44.
94. Thwaites D, McCann S, Broderick P: Hydromorphone neuroexcitation. J Palliat Med 2004;7:545-550.
95. Lee MA, Leng ME, Tiernan EJ: Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001;15:26-34.
96. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ: Symptom management in patients with established renal failure managed without dialysis. Edtna Erca J 2006;32:93-98.
97. Quigley C, Wiffen P: A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage 2003;25:169-178.
98. Sarhill N, Walsh D, Nelson KA: Hydromorphone: Pharmacology and clinical applications in cancer patients. Support Care Cancer 2001;9:84-96.
99. Cleary JF: Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997;24(5 Suppl 16):S16-19.
100. Streisand JB, Busch MA, Egan TD, Smith BG, Gay M, Pace NL: Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998;88:305-309.
101. Labroo RB, Paine MF, Thummel KE, Kharasch ED: Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997;25:1072-1080.
102. Kharasch ED, Hoffer C, Whittington D: Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology 2004;101:738-743.
103. Thompson JP, Bower S, Liddle AM, Rowbotham DJ: Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 1998;81:152-154.
104. Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S, Pinguet F: Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit 2005;27:491-498.
105. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-616.
106. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, Chavez J, Ashley J, Lebo D, Mc-Cracken M, Portenoy RK: Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:123-130.
107. Finn J, Wright J, Fong J, Mackenzie E, Wood F, Leslie G, Gelavis A: A randomised crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adult patients with burns. Burns 2004;30:262-268.
108. Zeppetella G: Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat Med 2000;14:57-58.
109. Soares LG, Martins M, Uchoa R: Intravenous fentanyl for cancer pain: A "fast titration" protocol for the emergency room. J Pain Symptom Manage 2003;26:876-881.
110. Davis MP, Weissman DE, Arnold RM: Opioid dose titration for severe cancer pain: A systematic evidence-based review. J Palliat Med 2004;7:462-468.
111. Sathyan G, Guo C, Sivakumar K, Gidwani S, Gupta S: Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005;21:1961-1968.
112. Freynhagen R, von Giesen, Busche P, Sabatowski R, Konrad C, Grond S: Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005;30:289-297.
113. Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturrisi CE, Foley KM: Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993;78:36-43.
114. Payne R, Chandler S, Einhaus M: Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs 1995;6(Suppl 3):50-53.
115. Mystakidou K, Tsilika E, Parpa E, Kouloulias V, Kouvaris I, Georgaki S, Vlahos L: Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer 2003;107:486-492.
116. Mystakidou K, Parpa E, Tsilika E, Katsouda E, Kouloulias V, Kouvaris J, Georgaki S, Vlahos L: Pain management of cancer patients with transdermal fentanyl: A study of 1828 step I, II, & III transfers. J Pain 2004;5:119-132.
117. Tawfik MO, Bryuzgin V, Kourteva G: Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Curr Med Res Opin 2004;20:259-267.
118. Regnard C, Pelham A: Severe respiratory depression and sedation with transdermal fentanyl: Four case studies. Palliat Med 2003;17:714-716.
119. Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F: Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 2006;14:400-407.
120. Korte W, de Stoutz N, Morant R: Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: Short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996;11:139-146.
121. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R: Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998;16:1588-1593.
122. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997;13:254-261.
123. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 2001;322:1154-1158.
124. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S: Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: A randomized controlled trial. JAMA 2004;291:1333-1341.
125. Poyhia R, Seppala T, Olkkola KT, Kalso E: The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992;33:617-621.
126. Kalso E, Vainio A: Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47:639-646.
127. Leow KP, Smith MT, Watt JA, Williams BE, Cramond T: Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992;14:479-484.
128. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59:52-61.
129. Kokki H, Rasanen I, Reinikainen M, Suhonen P, Vanamo K, Ojanpera I: Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet 2004;43:613-622.
130. Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T: Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991;35:642-646.
131. Heiskanen T, Kalso E: Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73:37-45.
132. Tallgren M, Olkkola KT, Seppala T, Hockerstedt K, Lindgren L: Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997;61:655-661.
133. Kirvela M, Lindgren L, Seppala T, Olkkola KT: The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996;8:13-18.
134. Lee MA, Leng ME, Cooper RM: Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Palliat Med 2005;19:259-260.
135. Heiskanen T, Olkkola KT, Kalso E: Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64:603-611.
136. Cleary J, Mikus G, Somogyi A, Bochner F: The influence of pharmacogenetics on opioid analgesia: Studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. J Pharmacol Exp Ther 1994;271:1528-1534.
137. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32:447-454.
138. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clin Pharmacol Ther 2006;79:461-479.
139. Sinatra R, Chung KS, Silverman DG, Brull SJ, Chung J, Harrison DM, Donielson D, Weinstock A: An evaluation of morphine and oxymorphone administered via patient-controlled analgesia (PCA) or PCA plus basal infusion in postcesarean-delivery patients. Anesthiology 1989;71:502-507.
140. Sloan P, Slatkin N, Ahdieh H: Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: A pilot study. Support Care Cancer 2005;13:57-65.
141. Adams MP, Ahdieh H: Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D 2005;6:91-99.
142. Gabrail NY, Dvergsten C, Ahdieh H: Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study. Curr Med Res Opin 2004;20:911-918.
143. Beaver WT, Wallenstein SL, Houde RW, Rogers A: Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer. J Clin Pharmacol 1977;17:186-198.
144. Prommer E: Oxymorphone: A review. Support Care Cancer 2006;14:109-115.
145. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-269.
146. Dale O, Sheffels P, Kharasch ED: Bioavailabilities of rectal and oral methadone in healthy subjects. Br J Clin Pharmacol 2004;58:156-162.
147. Ferrari A, Coccia CP, Bertolini A, Sternieri E: Methadone - Metabolism, pharmacokinetics and interactions. Pharmacol Res 2004;50:551-559.
148. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM: Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987;41:392-401.
149. Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001;9:73-83.
150. Oda Y, Kharasch ED: Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): Potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001;298:1021-1032.
151. Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB: Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003;69:205-211.
152. Lotsch J, Skarke C, Liefhold J, Geisslinger G: Genetic predictors of the clinical response to opioid analgesics: Clinical utility and future perspectives. Clin Pharmacokinet 2004;43:983-1013.
153. Elliott K, Kest B, Man A, Kao B, Inturrisi CE: N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology 1995;13:347-356.
154. Morley JS, Bridson J, Nash TP, Miles JB, White S, Makin MK: Low-dose methadone has an analgesic effect in neuropathic pain: A double-blind randomized controlled crossover trial. Palliat Med 2003;17:576-587.
155. Gagnon B, Bruera E: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999;18:120-125.
156. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, Strasser , Willey J, Bertolino M, Mathias C, Spruyt O, Fisch MJ: Methadone versus morphine as a first-line strong opioid for cancer pain: A randomized, double-blind study. J Clin Oncol 2004;22:185-192.
157. Inturrisi CE: Pharmacology of methadone and its isomers. Minerva Anestesiol 2005;71:435-437.
158. Chizh BA, Schlutz H, Scheede M, Englberger W: The Nmethyl-D-aspartate antagonistic and opioid components of d-methadone antinociception in the rat spinal cord. Neurosci Lett 2000;296:117-120.
159. Ripamonti C, Groff l, Brunelli C, Polastri D, Stavrakis A, De Conno F: Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? see comments. J Clin Oncol 1998;16:3216-3221.
160. Morley J, Watt J, Wells J: Methadone in pain uncontrolled by morphine. Lancet 1993;342:1243.
161. Mercadante S, Bianchi M, Villari P, Ferrera P, Casuccio A, Fulfaro F, Gebbia V: Opioid plasma concentration during switching from morphine to methadone: Preliminary data. Support Care Cancer 2003;11:326-331.
162. Dunlop R: Cancer: Palliative Care. Focus on Cancer. London/New York: Springer, 1998.
163. De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 1996;14:2836-2842.
164. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS: Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-504.
165. Kornick CA, Kilborn MJ, Santiago-Palma J, Schulman G, Thaler HT, Keefe DL, Katchman AN, Pezzullo JC, Ebert SN, Woosley RL, Payne R, Manfredi PL: QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.
166. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS: Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-805.
167. Walker PW, Klein D, Kasza L: High dose methadone and ventricular arrhythmias: A report of three cases. Pain 2003;103:321-324.
168. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M: Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients-a cross-sectional study. Addiction 2007;102:289-300.
169. Reddy S, Fisch M, Bruera E: Oral methadone for cancer pain: No indication of Q-T interval prolongation or torsades de pointes. J Pain Symptom Manage 2004;28:301-303.
170. Sittl R: Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 2006;20(Suppl 1):s25-30.
171. Walsh SL, Preston KL, Bigelow GE, Stitzer ML: Acute administration of buprenorphine in humans: Partial agonist and blockade effects. J Pharmacol Exp Ther 1995;274:361-372.
172. Dahan A: Opioid-induced respiratory effects: New data on buprenorphine. Palliat Med 2006;20(Suppl 1):s3-8.
173. Singhal A, Tripathi BM, Pal HR, Jena R, Jain R: Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance. Addict Behav 2007;32:320-331.
174. Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M, Schuttler J: Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005;118:15-22.
175. Filitz J, Griessinger N, Sittl R, Likar R, Schuttler J, Koppert W:
176. Boger RH: Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006;20(Suppl 1):s17-23.
177. Sorge J, Sittl R: Transdermal buprenorphine in the treatment of chronic pain: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1808-1820.
178. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E: Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. J Pain Symptom Manage 2001;22:672-687.
179. Nicholson, A.B., Methadone for cancer pain. Cochrane Database Syst Rev, 2004(2):CD003971.
180. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M: Changing pattern of agitated impaired mental status in patients with advanced cancer: Association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995;10:287-291.
181. Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004(3):CD004847.
182. Hagen N, Fisher K, Stiles C: Sublingual methadone for the management of cancer-related breakthrough pain: A pilot study. J Palliat Med 2007;10:331-337.
183. Leow KP, Cramond T, Smith MT: Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995;80:296-302.
184. Davis MP: Acute pain in advanced cancer: An opioid dosing strategy and illustration. Am J Hosp Palliat Care 2004;21:47-50.
185. Wolfe JM, Smithline HA, Phipen S, Montano G, Garb JL, Fiallo V: Does morphine change the physical examination in patients with acute appendicitis? Am J Emerg Med 2004;22:280-285.
186. Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML: The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 2000;49:207-214.
187. Klepstad P, Hilton P, Moen J, Kaasa S, Borchgrevink PC, Zahlsen K, Dale O: Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study. BMC Clin Pharmacol 2004;4:7.
188. Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: A retrospective, multicenter study. J Pain Symptom Manage 1996;11:71-80.
189. Prager JP: Neuraxial medication delivery: The development and maturity of a concept for treating chronic pain of spinal origin. Spine 2002;27:2593-2605; discussion 2606.
190. George MJ: The site of action of epidurally administered opioids and its relevance to postoperative pain management. Anaesthesia 2006;61:659-664.
191. Van Dongen RT, Crul BJ, De Bock M: Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: A retrospective analysis of 51 cases. Pain 1993;55:119-123.
192. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D: Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995;61:391-399.
193. Smith TJ, Staats S, Deer T, Stearns LJ, Rauck RJ, Boortz-Marx RL, Buchser E, Catala E, Bryce DA, Coyne PJ, Pool GE: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002;20:4040-4049.
194. Shamoon M, Hochberg MC: Treatment of osteoarthritis with acetaminophen: efficacy, safety, and comparison with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 2000;2:454-458.
195. Stockler M, Vardy J, Pillai A, Warr D: Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: A randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004;22:3389-3394.
196. Makin AJ, Williams R: Acetaminophen-induced hepatotoxicity: Predisposing factors and treatments. Adv Intern Med 1997;42:453-483.
197. Kurtovic J, Riordan SM: Paracetamol-induced hepatotoxicity at recommended dosage. J Intern Med 2003;253:240-243.
198. Blantz RC: Acetaminophen: Acute and chronic effects on renal function. Am J Kidney Dis 1996;28(1 Suppl 1):S3-6.
199. Mercadante S, Fulfaro F, Casuccio A: A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy. Effects on dose-escalation and a pharmacoeconomic analysis. Eur J Cancer 2002;38:1358-1363.
200. Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, Kimmel S, Carson JL: Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study. JAMA 1996;275:376-382.
201. Feldman HI, Kinman JL, Berlin JA, Hennessy S, Kimmel SE, Farrar J, Carson JL, Strom BL, Parenteral ketorolac: The risk for acute renal failure. Ann Intern Med 1997;126:193-199.
202. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB: NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005(1):CD005180.
203. Zelcer S, Kolesnikov Y, Kovalyshyn I, Pasternak DA, Pasternak GW: Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. Brain Res 2005;1040:151-156.
204. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH: Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305.
205. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA: A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-227.
206. Backonja MM: Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002;59(5 Suppl 2):S14-17.
207. Haddad A, Davis M, Lagman R: The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: Review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007;15:251-257.
208. Beydoun A, Kobetz S, Carrazana E: Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain 2004;20:174-178.
209. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280:1837-1842.
210. Rice A, Maton S, P.N.S. Group: Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo controlled study. Pain 2001;94:215-224.
211. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes VM, LaMoreaux L, Garofalo E: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998;280:1831-1836.
212. Caraceni A, Zecca E, Martini C, De Conno F: Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999;17:441-445.
213. Bosnjak S, Jelic S, Susnjar S, V. Luki, Gabapentin for relief of neuropathic pain related to anticancer treatment: A preliminary study. J Chemother 2002;14:214-219.
214. Mellegers MA, Furlan AD, Mailis A: Gabapentin for neuropathic pain: Systematic review of controlled and uncontrolled literature. Clin J Pain 2001;17:284-95.
215. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Tur RY, Maltoni M, VisentinM, Gorni G, Martini C, Tirelli W, Barbieri M, De Conno F: Gabapentin for neuropathic cancer pain: A randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22:2909-2917.
216. Berger A, Dukes E, McCarberg B, Liss M, Oster G: Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia. Clin Ther 2003;25:2809-2821.
217. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-1334.
218. Lesser H, Sharma U, LaMoreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004;63:2104-2110.
219. Richter RW, Portenoy R, Sharma R, Lamoreaux L, Bockbrader H, Knapp LE: Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005;6:253-260.
220. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U: Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004;110:628-638.
221. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS: Lamotrigine for central poststroke pain: A randomized controlled trial. Neurology 2001;56:184-190.
222. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K: A placebo-controlled trial of lamotigine for painful HIV-associated neuropathy. Neurology 2000;54:2115-2119.
223. Sindrup SH, Jensen TS: Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action. Pain 1999;83:389-400.
224. Mochizucki D: Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol 2004;19(Suppl 1):S15-19.
225. Max MB, Kishore-Kumar R, Schafer SC, Meister B, Gracely RH, Smoller B, Dubner R: Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial. Pain 1991;45:3-9; discussion 1-2.
226. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, TravisonG, Sabeen S, Royall RM, Max MB: Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2002;59:1015-1021.
227. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.
228. Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: A double-blind, placebo-controlled study. Pain 2004;110:697-706.
229. Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS: Venlafaxine versus imipramine in painful polyneuropathy: A randomized, controlled trial. Neurology 2003;60:1284-1289.
230. Tasmuth T, Hartel B, Kalso E: Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 2002;6:17-24.
231. Reuben SS, Makari-Judson G, Lurie SD: Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 2004;27:133-139.
232. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S: Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-118.
233. Vaghadia H, al-Ahdal OA, Nevin K: EMLA patch for intravenous cannulation in adult surgical outpatients. Can J Anaesth 1997;44:798-802.
234. Rowbotham MC, Davies PS, Verkempinck C, Galer BS: Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44.
235. Galer BS, Rowbotham MC, Perander J, Friedman E: Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain 1999;80:533-538.
236. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC: The lidocaine patch 5% effectively treats all neuropathic pain qualities: Results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002;18:297-301.
237. Devers A, Galer BS: Topical lidocaine patch relieves a variety of neuropathic pain conditions: An open-label study. Clin J Pain 2000;16:205-208.
238. Campbell BJ, Rowbotham M, Davies PS, Jacob P, 3rd, Benowitz NL: Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91:1343-1350.
239. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS: Analgesic therapy in postherpetic neuralgia: A quantitative systematic review. PLoS Med 2005;2:e164.
240. Kalso E, Tramer MR, McQuay HJ, Moore RA: Systemic local-anaesthetic-type drugs in chronic pain: A systematic review. Eur J Pain 1998;2:3-14.
241. Challapalli V, Tremont-Lukats I, McNicol E, Lau J, Carr D, Tremont-Lukats I: Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2005(4):CD003345.
242. Thomas J, Kronenberg R, Cox MC, Naco GC, Wallace M, von Gunten CF: Intravenous lidocaine relieves severe pain: Results of an inpatient hospice chart review. J Palliat Med 2004;7:660-667.
243. Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Crain GM, Markwell SJ, Jung S: A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993;16:1103-1115.
244. Jarvis B, Coukell AJ: Mexiletine. A review of its therapeutic use in painful diabetic neuropathy. Drugs 1998;56:691-707.
245. Chabal C, Jacobson L, Russell LC, Burchiel KJ: Pain response to perineuromal injection of normal saline, epinephrine, and lidocaine in humans. Pain 1992;49:9-12.
246. Wallace MS, Magnuson S, Ridgeway B: Efficacy of oral mexiletine for neuropathic pain with allodynia: A double-blind, placebo-controlled, crossover study. Reg Anesth Pain Med 2000;25:459-467.
247. Sloan P, Basta M, Storey P, von Gunten C: Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain. Anesth Analg 1999;89:760-761.
248. Galer BS, Harle J, Rowbotham MC: Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: A prospective study. J Pain Symptom Manage 1996;12:161-167.
249. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB: High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997;48:1212-1218.
250. Sang CN, Booher S, Gilron I, Parada S, Max MB: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: Efficacy and dose-response trials. Anesthesiology 2002;96:1053-1061.
251. Galer BS, Lee D, Ma T, Nagle B, Schlagheck TG: MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 2005;115:284-295.
252. Oga K, Kojima T, Matsuura M, Nagashima M, Kato J, Saeki S, Ogawa S: Effects of low-dose ketamine on neuropathic pain: An electroencephalogram- electrooculogram/behavioral study. Psychiatry Clin Neurosci 2002;56:355-363.
253. Sang CN: NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials. J Pain Symptom Manage 2000;19(1 Suppl):S21-25.
254. Bell R, Eccleston C, Kalso E: Ketamine as adjuvant to opioids for cancer pain. A qualitative systemic review. J Pain Symptom Manage 2003;26:867.
255. Szallasi A, Blumberg PM: Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-212.
256. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ: Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328:991.
257. Byas-Smith MG, Max MB, Muir J, Kingman A: Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain 1995;60:267-274.
258. Zeigler D, Lynch SA, Muir J, Benjamin J, Max MB: Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 1992;48:403-408.
259. Wallace MS: Ziconotide: A new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 2006;6:1423-1428.
260. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, Fisher R, Bryce DA, Mangieri EA, Luther RR, Mayo M, McGuire D, Ellis D: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: A randomized controlled trial. JAMA 2004;291:63-70.
261. Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R: A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31:393-406.
262. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
263. Wong R, Wiffen PJ: Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002(2):CD002068.
264. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W: Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003;21:3335-3342.
265. Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF, Tripathy D, Bergstrom B: Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004;111:306-312.
266. McQuay HJ, Collins SL, Carroll D, Moore RA: Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2000(2):CD001793.
267. Martinez-Zapata MJ, Roqué M, Alonso-Coello P, Català E: Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2006(3). Art. No.: CD003223. DOI: 10.1002/14651858.CD003223.pub2.